1

About ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)

News Discuss 
The current work examined the potential of employing ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant moreover palbociclib. ARV-825 was effective in both of those p53 wild-type (WT) breast tumor cells As well as in cells lacking purposeful p53 both by itself or in combination with tamoxifen, https://ermaq988epz1.yourkwikimage.com/user

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story